

Advancing the Development of Pediatric Therapeutics (ADEPT 6)

Pediatric Clinical Trial Endpoints for Rare Diseases with a Focus on Pediatric Patient Perspectives

FDA White Oak Campus, Building 31 (Great Room), Silver Spring, MD Tuesday, November 12, 2019

AGENDA			
8:00 - 8:15	Welcome and Introduction	Susan McCune, FDA	
8:15 – 8:35	Keynote Speaker – Theme: including pediatric patients from start to finish	Janet Maynard, FDA Scott Espich, Pediatric Patient Voice	
MORNING SESSION: CHOOSING ENDPOINTS			
8:35 – 9:00 Interview with Pediatric Patients			
9:00 – 10:00	Endpoints for pediatric patients: Are we asking the right questions? • Focus on fundamentals (age-	Ali Mohamadi, BioMarin Heather Adams, Univ. Rochester	
	appropriate endpoints for growth/development)	Tonya Palermo, Seattle Children's Hospital	
	Rare diseases/Common problems – (endpoints for sleep, pain, etc.)	поѕрітаї	
10:00 – 10:15	BREAK		
10:15 – 11:15	Individualized endpoints	Lili Garrard , FDA	
	Building bridges to novel endpoints	Patroula Smpokou, FDA Jin Shei Lai, Northwestern Univ.	
11:15 – 12:00	Panel Discussion/Q&A	Moderator: Pamela Gavin, NORD	
12:00 – 1:00	LUNCH		
AFTERNOON SESSION: MEASURING ENDPOINTS			
1:00 - 1:20	Interview with Pediatric Patients		
1:20 – 2:20	Data Collection: Old Ways and NewCOAs for children	Courtney Blackwell, Northwestern Bradley Marino, Lurie Children's	
	Patient registries – Pediatric Migraine Registry case study	Christoph Hornik, Duke	

*continued on reverse

2:20 – 2:40	BREAK	
	Real World Evidence	Robbert Zusterzeel, Medical Device Innovation Consortium
2:40 – 3:20		Device innovation consortium
	 Child- and youth-friendly technology – role of apps & devices 	Lori Crosby, Cincinnati Children's
3:20 – 4:20	Panel Discussion/Q&A	Moderator: Charles Thompson,
		Pfizer
4:20 – 4:30	WRAP-UP/CLOSING REMARKS – Carla Epps, FDA	